Funding
Some of the companies on this site pay us. That is a conflict of interest, and the only useful thing a disclosure page can do is show you exactly where it sits, so you can watch it. This one names the partners, the pages, and the buttons.
We belong to an affiliate network called Katalys. When you click a partner link here and go on to start care with that company, the company pays the network a commission and the network pays us a share. We are paid on the outcome, not on the click, and the whole arrangement is with the telehealth company — never with a drug manufacturer.
You pay nothing extra for arriving through us. The price is the company's price. There is no reader-side discount either, and if a company ever offers one we will say so on the page rather than pretending the link is neutral.
Some of them. We have partner arrangements with many of the companies on this site and with none of the others, and the split changes whenever a program opens or closes. We are not going to print a roster here that is out of date by the time you read it.
You never have to take this page's word for it, which is the point. Every review says on the page itself whether that company pays us, next to the price and again next to the button. One field on our roster drives both the label and the link, so a paid link cannot appear without the disclosure that belongs to it, and the two can never drift apart.
All of them run through /go/ on this domain and are tagged as sponsored. There are exactly five places one can appear:
The footer of this site carries no paid link on any page — navigation and disclosures only. Neither do our comparison pages, our method page, this page, or any of the legal pages. A non-partner's review has no sticky bar and no paid button anywhere on it, because there is nothing on it we are being paid to point at.
On a review of a company that does not pay us, clicking through to that company can open a panel offering one alternative that does. We would rather describe it here than have you discover it.
The rules it runs under: it never appears on a company that pays us, so it can never be used to move you between two of our own partners. The link you clicked always still works, and the "continue" option keeps your original destination untouched. Inside the panel, the paid option is disclosed as paid in the sentence above the button — not in a footnote — and its price is the same month-to-month number we publish everywhere else, pulled from the same roster. It offers an alternative, never a rank or a score. It shows up at most three times in a session, once per company. And it is capped, quiet, and skippable by design: if your browser blocks the storage it needs, it never fires at all.
We also test four different headlines on it and record which one you saw. That is a wording experiment, and it is described in the privacy policy along with the keys it writes.
Nobody can buy a position on this site. Each board prints its rule at the top and applies it to the entire roster, partners and non-partners alike, computed from the price data rather than typed by hand.
The test of that is what the boards look like today. On the cheapest list, 9 of the top 10 positions belong to companies that pay us nothing. Collective holds first place at $59 a month plus a $199 membership billed once a year (≈ $75.58/mo over a year, by our math), and it is one of our partners. The cheapest company on that board that does pay us sits at number 1 of 293. If commission set the order, that page would look very different, and you would be right to stop trusting it.
A rating. A position. A price. Every figure we publish is the month-to-month rate read off the company's own page, with the month we read it, never the prepay rung they advertise — and when a required membership sits on top of the medication price, we add it, because quoting the medication alone would repeat the company's own trick. When a company publishes no price before an intake, the review says exactly that rather than estimating one.
It does not buy a kind review. A partner that ships slowly is written up as a partner that ships slowly. A partner with an FDA warning letter gets that letter recorded and dated on its review, the same as anyone else — disclosure, not disqualification, applied to the companies that pay us and the ones that do not.
It does not buy silence about the competition. We review companies with no program at all and say plainly when they beat our partners on price, because a list that only ever ranked our partners first would be worth nothing to you and, before long, nothing to us either.
An independent publisher, and nothing else. Not a pharmacy, not a prescriber, not a telehealth service, and not a party to whatever you buy. We hold no relationship with Novo Nordisk, Eli Lilly, or any other manufacturer — see trademarks. Nothing here is medical advice; the medical disclaimer covers that, and prices and state availability move constantly, so check the company's own site before you buy.
desk@glpamerica.org. A wrong price gets the source page re-read and the fix dated on the review. A missed conflict gets disclosed. If you think a partner is getting an easier ride than the evidence supports, say so and name the sentence — that is the complaint we most want to receive.
How the reviews themselves are built is on how we review; the reading and quoting rules are in the terms of use. Everything on glpamerica.org is written by GLP America.